Sign in

India to launch indigenous vaccine against cervical cancer today

India’s first indigenously developed quadrivalent Human Papilloma Virus (HPV) vaccine for the prevention of cervical cancer will be launched here on Thursday, officials said on Wednesday.

Updated on: Sep 1, 2022, 04:42:47 IST
By , New Delhi
Share
Share via
  • facebook
  • twitter
  • linkedin
Copy link
  • copy link

India’s first indigenously developed quadrivalent Human Papilloma Virus (HPV) vaccine for the prevention of cervical cancer will be launched here on Thursday, officials said on Wednesday.

India’s first indigenously developed quadrivalent Human Papilloma Virus (HPV) vaccine for the prevention of cervical cancer will be launched today.
India’s first indigenously developed quadrivalent Human Papilloma Virus (HPV) vaccine for the prevention of cervical cancer will be launched today.

The Drugs Controller General of India (DCGI) had last month granted market authorisation to Serum Institute of India (SII) to manufacture an indigenously-developed vaccine against cervical cancer.

Also read: Only 12% in 18-59 age group have taken Covid vaccine booster dose: Data

Union Minister of Science and Technology Jitendra Singh will launch the vaccine at IIC Delhi. SII CEO Adar Poonawalla will be present at the event, the officials said.

According to the officials, the qHPV vaccine CERVAVAC has demonstrated robust antibody response that is nearly 1,000 times higher than the baseline against all targeted HPV types and in all dose and age groups.

Cervical cancer in India ranks as the second most frequent cancer among women between 15 and 44 years of age.

Also read: Ahead of Ganpati festival, only two mandals seek vaccination drive

The DCGI’s approval had come following recommendation by the Subject Expert Committee (SEC) on COVID-19 of the CDSCO on June 15 after Prakash Kumar Singh, director (government and regulatory affairs) at Serum Institute, had applied to the DCGI seeking market authorisation of qHPV after the phase second and third clinical trial was completed with support of the Department of Biotechnology under the Ministry of Science and Technology to ensure its early availability.

  • HT News Desk
    ABOUT THE AUTHOR
    HT News Desk

    Follow the latest breaking news, major developments and agenda-setting stories from India and around the world with the newsdesk at Hindustan Times. Operating round the clock, the desk brings together experienced editors, reporters and correspondents to deliver fast, accurate and contextual reporting across subjects that influence public policy, governance, business, society and international affairs. The HT News Desk covers politics, elections, government policies, the economy, business and markets, science and technology, the environment, law and order, infrastructure, education, climate issues and geopolitics, while closely tracking developments across states, institutions and global capitals. The team also leads coverage of major breaking news events, policy announcements, court proceedings, natural disasters, public emergencies and significant international developments. Reports published by the newsdesk are based on information gathered from reporters on the ground, official statements, government agencies, court records, regulatory filings, recognised institutions and other authoritative sources. Stories undergo editorial scrutiny and verification processes to ensure accuracy, fairness and relevance, and are updated as events evolve and additional information becomes available. Whether covering a key political decision in New Delhi, an economic policy shift affecting millions, a landmark court ruling or a major global event, the HT News Desk aims to provide readers with reliable, fact-based journalism that delivers not only the latest developments but also the context and analysis needed to understand their wider implications.Read More